|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-22
|
|
pubmed:abstractText |
Intestinal inflammation is a component of the pathophysiology of protein-losing enteropathy after the Fontan operation. Oral controlled-release budesonide is 90% metabolized at first pass through the liver, has high enteric anti-inflammatory activity and relatively low systemic effects, and may be an ideal agent for use in treating this disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1552-6259
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
837-42
|
|
pubmed:meshHeading |
pubmed-meshheading:20172140-Administration, Oral,
pubmed-meshheading:20172140-Adolescent,
pubmed-meshheading:20172140-Adult,
pubmed-meshheading:20172140-Anti-Inflammatory Agents,
pubmed-meshheading:20172140-Budesonide,
pubmed-meshheading:20172140-Female,
pubmed-meshheading:20172140-Fontan Procedure,
pubmed-meshheading:20172140-Humans,
pubmed-meshheading:20172140-Male,
pubmed-meshheading:20172140-Protein-Losing Enteropathies,
pubmed-meshheading:20172140-Serum Albumin,
pubmed-meshheading:20172140-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.
|
|
pubmed:affiliation |
Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.
|
|
pubmed:publicationType |
Journal Article
|
